<DOC>
	<DOCNO>NCT02333929</DOCNO>
	<brief_summary>The objective study demonstrate performance STA® - Rivaroxaban Calibrator STA® - Rivaroxaban Control combination STA® - Liquid Anti-Xa determine quantity rivaroxaban plasma sample measurement direct anti-Xa activity .</brief_summary>
	<brief_title>Validation Rivaroxaban Assay US Registration</brief_title>
	<detailed_description>The study method comparison reference method ( LCMS ) candidate device . Between 90 120 sample obtain patient treated rivaroxaban collect 3 site US accord inclusion exclusion criterion detail protocol . These sample freeze collection send hemostasis laboratory test LCMS central laboratory validate rivaroxaban measurement . Results express ng/mL obtain STA® - Liquid Anti-Xa , use combination STA® - Rivaroxaban Calibrator STA® - Rivaroxaban Control compare result obtain LCMS laboratory . Diagnostica Stago analyse result thanks regression accord CLSI EP9-A3 recommendation ( guideline dedicate method comparison quantitative assay ) order support equivalence 2 method .</detailed_description>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Between 30 40 samples/site obtain patient treated rivaroxaban . ( ideally 1015 sample per indication per site depend site practice ) : Prophylaxis VTE patient undergo knee hip replacement surgery ( 10 mg OD ) : orthopaedic department hospital charge sample collection . Treatment deep vein thrombosis ( DVT ) , pulmonary embolism ( PE ) , risk reduction DVT PE recurrence ; ( 15 mg BID 3 week 20 mg OD ) : different department hospital charge sample collection ( sample come e.g. , emergency room , vascular lab cancer unit ) . Stroke prevention reduction systemic embolism nonvalvular patient atrial fibrillation ( SPAF ) ( 20 mg OD ) : cardiology department hospital charge sample collection . Patients le 18 year old Patients anticoagulant treatment Samples collect , store , handle accordance sample collection procedure define CLSI H21A5</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>rivaroxaban</keyword>
	<keyword>NOAC</keyword>
	<keyword>anti-Xa activity</keyword>
	<keyword>method comparison</keyword>
	<keyword>LCMS</keyword>
</DOC>